Global Cardiovascular Drugs Market Size By Drug Class (Anti hyperlipidemics, Anti-hypertensives, Anti-coagulants), By Indications (Hypertension, Hyperlipidemia, Coronary Artery Disease), By Distribution Channels (Hospital Pharmacies, Online Pharmacies), By Geographic Scope And Forecast

Cardiovascular Drugs Market Size And Forecast

Cardiovascular Drugs Market size was valued at USD 48 Billion in 2021 and is projected to reach USD 75 Billion by 2030, growing at a CAGR of 3.5% from 2023 to 2030.

The growing number of people in the geriatric age group has increased the sales and demand for cardiovascular drugs. The increasing number of chronic diseases among people has increased the sales and demand for cardiovascular drugs. The Global Cardiovascular Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cardiovascular Drugs Market Definition

The Global Cardiovascular Drugs Market is expected to witness high growth mainly due to the increasing incidence of people suffering from cardiovascular diseases. Cardiovascular disease (CVD) is a class of diseases that affect the heart or blood vessels. Cardiovascular diseases are one of the leading causes of death worldwide. Cardiovascular disease includes coronary artery disease (CAD), such as angina pectoris and myocardial infarction (heart attack). Other cardiovascular diseases include stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, cardiac arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral artery disease, thromboembolic disease, and venous thrombosis.

Global Cardiovascular Drugs Market Overview

The growing number of people in the geriatric age group has increased the sales and demand for cardiovascular drugs. The increasing number of chronic diseases among people has increased the sales and demand for cardiovascular drugs. There are a number of chronic diseases that require only palliative treatment and cannot be permanently cured. As a result, the use of cardiovascular drugs has increased to a large extent. The major increasing problems of hypertension and cholesterol have increased the number of patients suffering from cardiovascular diseases. This has increased the sales and demand for cardiovascular drugs in the market.

These various reasons proved to be the driving factors for the growth of the market during the forecast period. The high cost associated with the use of cardiovascular drugs has hampered the growth of the market. Stringent government guidelines and norms regarding the use of cardiovascular drugs have hampered the growth of the market. The number of side effects and complications caused by cardiovascular drugs is holding back sales and demand. Growing health awareness has hampered the demand for cardiovascular drugs. With the advent of the pandemic, people began to care about their health, and therefore the number of people who need acute cardiovascular drugs decreased.

These numerous reasons have emerged as the restraining factors for the growth of the Cardiovascular Drugs Market. The huge number of people suffering from obesity and cholesterol increased the risk of cardiovascular disorders. The use of emergency medicine is common in hospitals, which has proven to be a great opportunity for market growth. A huge amount of patience goes into the palliative treatment of chronic diseases, which proves to be a constant sales in the market that keeps the sales revenue flowing. The number of people suffering from hypertension has also increased the use of cardiovascular drugs.

Blood thinners are in high demand in the market due to increased cardiovascular disorders. The increasing life expectancy of the geriatric population has boosted sales of cardiovascular drugs. The increasing prevalence of cardiovascular disorders in young people has boosted the sales of these emergency drugs. Hypertension drugs are not easily discontinued, which helps to continue the demand and supply of these drugs. These various reasons provide great opportunities for the market.

Global Cardiovascular Drugs MarketSegmentation Analysis

The Global Cardiovascular Drugs Market is segmented on the basis of Drug Class, Indications, Distribution Channels, and Geography.

Cardiovascular Drugs Market, By Drug Class

• Anti hyperlipidemics
• Anti-hypertensives
• Anti-coagulants
• Anti-fibrinolytics
• Anti-arrhythmic

Based on Drug Class, the market is segmented into Anti hyperlipidemics, Anti-hypertensives, Anti-coagulants, Anti-fibrinolytics, and Anti-arrhythmic.

Cardiovascular Drugs Market, By Indications

• Hypertension
• Hyperlipidemia
• Coronary Artery Disease
• Peripheral Artery Disease
• Arrhythmia
• Others

Based on Indications, the market is segmented into Hypertension, Hyperlipidemia, Coronary Artery Disease, Peripheral Artery Disease, Arrhythmia, and Others.

Cardiovascular Drugs Market, By Distribution Channels

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Based on Distribution Channels, the market is segmented into Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Cardiovascular Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, the Global Cardiovascular Drugs Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America accounted for the major share of the Global Cardiovascular Drugs Market. The Asia Pacific market is expected to gain market share during the forecast period and is likely to be a key source of revenue in the coming years. Local government initiatives to achieve self-sufficiency in drug manufacturing and incentives for generic drug manufacturing in countries such as Brazil, South Africa, Saudi Arabia, etc. are likely to boost the market growth in South America, Middle East And Africa.

Key Players

The “Global Cardiovascular Drugs Market” study report will provide valuable insight with an emphasis on the global market including some of the major players are AstraZeneca plc., Bayer AG, Merck & Co., Inc., Sanofi, Pfizer, Eli Lilly & Company, Sanofi, Bayer Corp, Bristol-Myers Squibb Co, Daiichi Sankyo, Johnson & Johnson, Gilead Sciences Inc., Par Pharmaceutical, United Therapeutics, Nippon Shinyaku Co. Ltd., Lupin Atlantis Holdings, Silvergate Pharmaceuticals Inc., TSH Biopharm Corp., Novartis, Relypsa, Vectus Biosystems Ltd., Phasebio Pharmaceuticals, Ablative Solutions, Mylan Specialty, Curemark, and Takeda Pharmaceutical Co.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In January 2019 – Natco Pharma which is an Indian company. Natco Pharma Unveils Valsartan-Sacubitril Discovery. It is a cardiovascular drug used in the treatment of congestive heart failure. The patent is owned by Novartis AG under the Vymada banner.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Cardiovascular Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for understanding the behavior of competitors and a player’s strategic positioning in the respective industry. Porter’s five forces model can be used to assess the competitive landscape in Global Cardiovascular Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the regio